Article Text

Download PDFPDF
SNIS 8th annual meeting oral abstracts
O-005 Endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 h from time last seen well: a subset analysis of the merci registry
  1. R Nogueira1,
  2. M Rymer2,
  3. W Smith3,
  4. H Lutsep4,
  5. G Walker5,
  6. D Liebeskind6,
  7. R Budzik7,
  8. T Devlin8,
  9. T Jovin9
  1. 1Interventional Neurology, Emory University School of Medicine/Grady Memorial Hospital, Atlanta, Georgia, USA
  2. 2Department of Neurology, Saint Luke's Medical Center, Kansas City, Missouri, USA
  3. 3Department of Neurology, UCSF, San Francisco, California, USA
  4. 4Department of Neurology, Oregon Stroke Center, Oregon Health & Science University, Portland, OR
  5. 5Concentric Medical, Mountain View, California, USA
  6. 6Department of Neurology, UCLA, Los Angeles, California, USA
  7. 7Interventional Neurology, Riverside Methodist Hospital, Columbus, Ohio, USA
  8. 8Department of Neurology, Erlanger Medical Center, Chattanooga, Tennessee, USA
  9. 9Interventional Neurology, UPMC Stroke Institute, Pittsburgh, Pennsylvania, USA


Background and Purpose Current selection criteria for reperfusion therapy are based on strict time windows. Recent data suggest that the mismatch between stroke severity and the amount of ischemic core at presentation may be more important than time when selecting patients for reperfusion treatment. We describe a prospectively collected cohort of anterior circulation stroke patients treated beyond 8 h from time last seen well (TLSW).

Methods The Merci Registry was a multicenter prospective registry of stroke patients with acute proximal intracranial arterial occlusion treated with Merci thrombectomy with or without adjunctive use of other devices or drugs. We performed a subset analysis of all consecutive patients meeting the following criteria: (1) anterior circulation occlusion, (2) treatment initiated >8 h from TLSW.

Results A total of 1000 patients were enrolled. Out of these, 112 were treated >8 h from TLSW and had complete follow-up data. Their baseline characteristics were as following: mean age, 62.7±15.1; male gender, 56.3%; baseline NIHSS 15.05±5.8 (median 15); mean time from symptom onset to puncture (hr), 13.82±10.6 (median, 10.74); mean procedural duration (hr), 2.06±1.0 (median 1.95); IV rt-PA use, 10.7%; IA thrombolytic use, 42%; GpIIbIIIa inhibitor use, 14.3%; other devices use, 46.5%; proximal occlusion stenting, 28.6%.The occlusion sites included: ICA, 41.1%; MCA-M1, 51.8%; MCA-M2, 7.1%. 50% of the patients had “wake-up” strokes while 18.8% of the patients had witnessed strokes with onset beyond 8 h from treatment. Successful revascularization (TICI≥2) was achieved in 81.3% (91/112) of the patients. Symptomatic intracranial hemorrhage (SICH) has been adjudicated according to the ECASS III criteria in 77/112 patients. There were 7/77 (9.1%) definite SICH and 4/77 uncertain SICH (5.2%) resulting a SICH rate not worse than 14.3%. The rate of good outcomes (90-day mRS≤2) was higher (37.8% vs 30.2%, p=0.12) and the 90-day mortality was significantly lower (18.8% vs 35.8%, p=0.0003) in the patients treated >8 h from TLSW as compared to the patients treated within 8 h. This was likely due to imbalances in age (67.5 vs 62.7) and baseline NIHSS (17.8 vs 15.05) as well as to a presumably higher rate of advanced (MRI or CT perfusion) imaging selection in the late treatment group. A subgroup of patients treated >8 h (n=50) was matched with PROACT-II patients for age (mean, 63 vs 64), baseline NIHSS (median, 17.5 vs 17), and site of occlusion (MCA-M1 and M2). These patients had similar rates of 90-day good outcome (36% vs 40%, p=NS) and mortality (16% vs 25%, p=NS) to the PROACT-II patients treated with intra-arterial therapy.

Conclusions In properly selected patients, endovascular therapy appears to be safe and beneficial even when treatment is initiated beyond 8 h from TLSW. The benefit of this approach compared to standard medical therapy should be assessed in a prospective randomized trial.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Disclosures R Nogueira: Concentric Medical, ev3 neurovascular, Coaxia. M Rymer: Concentric Medical. Genetech. W Smith: Concentric Medical. H Lutsep: Concentric Medical. G Walker: Concentric Medical. D Liebeskind: Concentric Medical, Coaxia. R Budzik: Concentric Medical. T Devlin: Concentric Medical. T Jovin: Concentric Medical, ev3 neurovascular, Coaxia.